Lantern Pharma (NASDAQ:LTRN) posted its quarterly earnings results on Sunday. The company reported ($0.24) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.27) by $0.03, MarketWatch Earnings reports.
LTRN stock traded down $0.32 during trading on Tuesday, hitting $15.66. 57,434 shares of the company’s stock traded hands, compared to its average volume of 195,705. The business has a fifty day simple moving average of $17.73 and a two-hundred day simple moving average of $17.15. The company has a debt-to-equity ratio of 0.01, a quick ratio of 27.58 and a current ratio of 27.58. Lantern Pharma has a 1 year low of $10.40 and a 1 year high of $24.84.
Lantern Pharma Company Profile
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on the development of precision oncology therapies using artificial intelligence, genomics, and machine learning. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, prostate cancer.
Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.